Equillium Inc (EQ)

$1.85 +0.11 (6.32%)
Market Cap 105.95M
Revenue (ttm) 41.10M
Net Income (ttm) -8.07M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -19.64%
Debt to Equity Ratio 0.00
Volume 250,000
Avg Vol 728,558
Day's Range N/A - N/A
Shares Out 60.89M
Stochastic %K 95%
Beta 1.87
Analysts Sell
Price Target $2.50

Company Profile

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 240 1200
Address:
2223 Avenida De La Playa, Suite 105, La Jolla, United States
Meowzilla1
Meowzilla1 Feb. 24 at 12:49 AM
:@SqueezeSharkie is operating on a whole different level, easily ahead of 90% of the traders on this platform. :If you’re not paying attention yet, you’re missing out. Go give him a follow. It’s completely free and only takes a second 💎 $HYMC $RBOT $CHSN $EQ on close watch
0 · Reply
BanditQ
BanditQ Feb. 23 at 9:08 PM
$EQ you should've bought when I told you, you fkn COWARD
0 · Reply
BanditQ
BanditQ Feb. 23 at 9:01 PM
$EQ juicy
0 · Reply
AngeloWhite795
AngeloWhite795 Feb. 21 at 8:23 AM
$EQ Equillium develops immunology therapies. Clinical milestones drive valuation. Early-stage risk remains.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 20 at 2:23 AM
$EQ RSI: 86.67, MACD: 0.1127 Vol: 0.16, MA20: 1.48, MA50: 1.34 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
AceofDiamonds
AceofDiamonds Feb. 19 at 8:54 PM
$EQ This stock is going to make many millionaires. Will be $15.00 when they sell right after Phase 1 data
1 · Reply
Yimmiedd
Yimmiedd Feb. 19 at 8:35 PM
$EQ $PALI $ABVX will these be ABVX takeout sympathy plays?
0 · Reply
annee33
annee33 Feb. 19 at 6:29 PM
$SEER and $EQ both under the radar biotechs hitting my breakout scan
0 · Reply
BanditQ
BanditQ Feb. 17 at 3:40 PM
$EQ ph1 data gradually getting priced in 👍
0 · Reply
CapitalUmbral
CapitalUmbral Feb. 17 at 3:06 PM
$EQ EQ or unknown ticker with limited public data.
0 · Reply
Latest News on EQ
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 2, 2026, 4:05 PM EST - 21 days ago

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equillium to Participate in Upcoming Investor Conferences

Nov 20, 2025, 4:35 PM EST - 3 months ago

Equillium to Participate in Upcoming Investor Conferences

Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update

Nov 13, 2025, 4:05 PM EST - 3 months ago

Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update

Equillium, Inc. (EQ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases Transcript

Nov 5, 2025, 6:21 PM EST - 3 months ago

Equillium, Inc. (EQ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases Transcript

Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025

Oct 22, 2025, 8:00 AM EDT - 4 months ago

Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025

Equillium Announces Leadership and Corporate Updates

Oct 6, 2025, 4:02 PM EDT - 5 months ago

Equillium Announces Leadership and Corporate Updates

NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor

Sep 23, 2025, 5:30 AM EDT - 5 months ago

NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor

Equillium to Participate in the Cantor Global Healthcare Conference 2025

Aug 29, 2025, 4:03 PM EDT - 6 months ago

Equillium to Participate in the Cantor Global Healthcare Conference 2025

Equillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UC

Aug 28, 2025, 5:35 PM EDT - 6 months ago

Equillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UC

Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic

Aug 11, 2025, 8:30 AM EDT - 7 months ago

Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic

Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy

Aug 4, 2025, 8:30 AM EDT - 7 months ago

Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

May 6, 2025, 8:00 AM EDT - 10 months ago

Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

May 1, 2025, 8:00 AM EDT - 10 months ago

Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504

Equillium Announces Feedback from the U.S. Food and Drug Administration

Apr 24, 2025, 9:00 AM EDT - 10 months ago

Equillium Announces Feedback from the U.S. Food and Drug Administration

Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients

Mar 27, 2025, 11:16 AM EDT - 11 months ago

Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Mar 27, 2025, 7:00 AM EDT - 11 months ago

Equillium Announces Results of the Phase 3 EQUATOR Study of Itolizumab in First-Line Treatment of Patients with Acute Graft-Versus-Host Disease

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights

Mar 27, 2025, 7:00 AM EDT - 11 months ago

Equillium Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate and Clinical Highlights

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

Feb 6, 2025, 8:00 AM EST - 1 year ago

Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

Nov 13, 2024, 4:01 PM EST - 1 year ago

Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates

Equillium to Present at the Stifel Healthcare Conference

Nov 13, 2024, 8:00 AM EST - 1 year ago

Equillium to Present at the Stifel Healthcare Conference

Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer

Nov 12, 2024, 8:00 AM EST - 1 year ago

Equillium Announces Poster Presentation at the Society for Immunotherapy of Cancer

Equillium Maintains Rights to Itolizumab Following Ono Partnership

Oct 31, 2024, 7:00 AM EDT - 1 year ago

Equillium Maintains Rights to Itolizumab Following Ono Partnership

Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer

Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit

Sep 10, 2024, 8:00 AM EDT - 1 year ago

Equillium to Present at the Stifel Virtual Inflammation & Immunology Summit

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference

Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Equillium Reports Second Quarter 2024 Financial Results and Provides Recent Corporate and Clinical Highlights

Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Positive Interim Analysis from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance

Jul 18, 2024, 1:57 PM EDT - 1 year ago

Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance

Equillium to be included in the Russell Microcap® Index

Jun 12, 2024, 8:00 AM EDT - 1 year ago

Equillium to be included in the Russell Microcap® Index

Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

Jun 4, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata

Equillium to Present at the Jefferies Global Healthcare Conference

May 29, 2024, 8:00 AM EDT - 1 year ago

Equillium to Present at the Jefferies Global Healthcare Conference

Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

May 14, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights

May 9, 2024, 4:01 PM EDT - 1 year ago

Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

May 7, 2024, 8:00 AM EDT - 1 year ago

Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

Mar 25, 2024, 4:01 PM EDT - 2 years ago

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

Mar 22, 2024, 8:00 AM EDT - 2 years ago

Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

Dec 21, 2023, 8:00 AM EST - 2 years ago

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

Nov 13, 2023, 9:00 AM EST - 2 years ago

Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology

Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Nov 8, 2023, 4:01 PM EST - 2 years ago

Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Nov 6, 2023, 8:00 AM EST - 2 years ago

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology

Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Equillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics Symposium

Equillium to Host Analyst & Investor Day

Oct 3, 2023, 8:00 AM EDT - 2 years ago

Equillium to Host Analyst & Investor Day

Equillium to Present at the JonesTrading 2023 Healthcare Summit

Oct 2, 2023, 8:00 AM EDT - 2 years ago

Equillium to Present at the JonesTrading 2023 Healthcare Summit

Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences

Sep 20, 2023, 8:00 AM EDT - 2 years ago

Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences

Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference

Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Aug 9, 2023, 4:01 PM EDT - 2 years ago

Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Equillium Announces $7.5 Million Share Repurchase Program

Aug 2, 2023, 4:00 PM EDT - 2 years ago

Equillium Announces $7.5 Million Share Repurchase Program

Meowzilla1
Meowzilla1 Feb. 24 at 12:49 AM
:@SqueezeSharkie is operating on a whole different level, easily ahead of 90% of the traders on this platform. :If you’re not paying attention yet, you’re missing out. Go give him a follow. It’s completely free and only takes a second 💎 $HYMC $RBOT $CHSN $EQ on close watch
0 · Reply
BanditQ
BanditQ Feb. 23 at 9:08 PM
$EQ you should've bought when I told you, you fkn COWARD
0 · Reply
BanditQ
BanditQ Feb. 23 at 9:01 PM
$EQ juicy
0 · Reply
AngeloWhite795
AngeloWhite795 Feb. 21 at 8:23 AM
$EQ Equillium develops immunology therapies. Clinical milestones drive valuation. Early-stage risk remains.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 20 at 2:23 AM
$EQ RSI: 86.67, MACD: 0.1127 Vol: 0.16, MA20: 1.48, MA50: 1.34 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
AceofDiamonds
AceofDiamonds Feb. 19 at 8:54 PM
$EQ This stock is going to make many millionaires. Will be $15.00 when they sell right after Phase 1 data
1 · Reply
Yimmiedd
Yimmiedd Feb. 19 at 8:35 PM
$EQ $PALI $ABVX will these be ABVX takeout sympathy plays?
0 · Reply
annee33
annee33 Feb. 19 at 6:29 PM
$SEER and $EQ both under the radar biotechs hitting my breakout scan
0 · Reply
BanditQ
BanditQ Feb. 17 at 3:40 PM
$EQ ph1 data gradually getting priced in 👍
0 · Reply
CapitalUmbral
CapitalUmbral Feb. 17 at 3:06 PM
$EQ EQ or unknown ticker with limited public data.
0 · Reply
Coleperris55
Coleperris55 Feb. 14 at 1:33 AM
$EQ Good risk reward here. My plan: Entry at current price: $1.57 Stop loss: $1.35 (14%) Take profit (downtrend resistance): $2.00 (27%) Overall, my price target is $2.00
0 · Reply
annee33
annee33 Feb. 12 at 3:48 PM
$EQ trying to breakout
0 · Reply
AceofDiamonds
AceofDiamonds Feb. 12 at 1:46 AM
$EQ Once internal data shows positive for Phase 1 this will sell just like its peers Morphic( Phase 2A, 3.2 Billion ), Prometheus ( Phase 2A, 10.8 Billion ), and Protagonist ( Preclinical 900 Million ), for over a billion at minimum. 10 times money from here on the low end. Just added more.
0 · Reply
QuietSweep
QuietSweep Feb. 10 at 1:22 PM
$EQ is an equipment or financial company; ticker too short for clear analysis.
0 · Reply
BanditQ
BanditQ Feb. 4 at 2:13 PM
$EQ the UC drug is basically the whole company now. So every positive/negative news is amplified
0 · Reply
WraithIcey
WraithIcey Feb. 2 at 7:44 PM
$EQ
0 · Reply
AceofDiamonds
AceofDiamonds Jan. 30 at 9:52 PM
$EQ It’s easy to see why the CEO just exercised options on 1.75 million shares. As soon as Phase 1 is completed like other similar drugs EQ is gonna sell for a massive payday.
0 · Reply
BanditQ
BanditQ Jan. 30 at 5:38 PM
$SLS if you want to make money BUY $EQ $6!!!
0 · Reply
Capitulation_0
Capitulation_0 Jan. 26 at 2:52 PM
$EQ same MOA as $ABVX... yes, they're far behind but it's far too cheap as well... if $ABVX gets bought, I expect this to go up in sympathy...
1 · Reply
echo_fable
echo_fable Jan. 24 at 3:07 PM
$EQ
0 · Reply
echo_fable
echo_fable Jan. 24 at 2:53 PM
$EQ Periods of reduced macro uncertainty and delayed economic data releases can create liquidity tailwinds for equities, giving growth indices like the Nasdaq room to rally without sharp policy-driven volatility.
0 · Reply
echo_fable
echo_fable Jan. 24 at 2:52 PM
$EQ
0 · Reply